Certolizumab pegol improves HRQoL in patients with Crohn's disease: Data from PRECiSE 2

被引：0
|
作者：
Feagan, B.
Keininger, D.
Coteur, G.
Schreiber, S.
机构：
[1] Robarts Res Inst, London, ON N6A 5C1, Canada
[2] Univ Kiel, Kiel, Germany
[3] SGS Life Sci Serv, Mechelen, Belgium
来源：
INFLAMMATORY BOWEL DISEASES | 2007年 / 13卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：661 / 662
页数：2
相关论文
共 50 条
  • [41] Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study
    Feagan, B. G.
    Reilly, M. C.
    Gerlier, L.
    Brabant, Y.
    Brown, M.
    Schreiber, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (12) : 1276 - 1285
  • [42] Baseline Corticosteroid Use and Corticosteroid-Free Clinical Remission in Crohn's Disease Patients Treated With Certolizumab Pegol in the PRECiSE 2 Trial
    Sandborn, William
    Feagan, Brian
    Lee, Scott
    Hanauer, Stephen
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S23 - S24
  • [43] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
    Sandborn, William J.
    Abreu, Maria T.
    D'Haens, Geert
    Colombel, Jean-Frederic
    Vermeire, Severine
    Mitchev, Krassimir
    Jamoul, Corinne
    Fedorak, Richard N.
    Spehlmann, Martina E.
    Wolf, Douglas C.
    Lee, Scott
    Rutgeerts, Paul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695
  • [44] Mucosal Healing in Patients Receiving Certolizumab Pegol for Crohn's Disease (CHARTER Study)
    Randall, Charles
    Herrera, Christian
    Taboada, Carlo
    Fincke, Christopher
    Havranek, Russell
    Zurita, Franz
    Stump, David
    Gossen, Gary
    Vidaurri, Daniela
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S436 - S437
  • [45] CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn's Disease patients with open fistulas
    Schreiber, S.
    Lawranc, I
    Thomsen, O.
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S1 - S1
  • [46] CERTOLIZUMAB PEGOL IN PATIENTS WITH CROHN'S DISEASE: A LONG TERM UPDATE OF COMPASSIONATE USE
    Mocciaro, F.
    Renna, S.
    Orlando, A.
    Olivo, M.
    Sinagra, E.
    Cottone, M.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S189 - S189
  • [47] Impact of Crohn's disease and treatment with certolizumab pegol 400 mg every 4 weeks on patient-reported health status: Data from PRECiSE 2
    Feagan, Brian G.
    Keininger, Dorothy L.
    Coteur, Geoffroy
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S404 - S404
  • [48] Certolizumab pegol as treatment for Crohn's disease in a community IBD practice
    Shafran, Ira
    Burgunder, Patricia
    Fakih, Faisal
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S27 - S27
  • [49] Long-term tolerability of subcutaneous certolizumab pegol in active Crohn's disease: Results from precise 3 and 4
    Colombel, Jean-frederic
    Schreiber, Stefan
    Hanauer, Stephen B.
    Rutgeerts, Paul
    Sandborn, William J.
    GASTROENTEROLOGY, 2007, 132 (04) : A503 - A503
  • [50] Long-Term Outcomes of Certolizumab Pegol for Crohn's Disease: 7 Year Results From the PRECiSE 3 Study
    Sandborn, William
    Lee, Scott D.
    Randall, Charles W.
    Gutierrez, Alexandra
    Schwartz, David A.
    Ambarkhane, Sumeet
    Kayhan, Cem
    Pierre-Louis, Bosny
    Kosutic, Gordana
    Schreiber, Stefan
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2014, 146 (05) : S588 - S589
12345